ELOVL1 and cancer: Stronger T cell activation was further validated in OT-I T cells genetically depleted for Elovl1. Upon 5 h of in vitro re-stimulation with KPC_OVA cancer cells, sgElovl1 OT-I T cells enhanced the release of cytotoxic granules compared with control OT-I T cells, as shown by higher exposure at the cell surface of CD107a, a surrogate marker of T cell degranulation and an indication of a stronger antigen recognition (Fig. 6n).